We found a weak association between TG-lowering therapies and aortic (ANGPTL3, 0.51, 0.29–0.89) and abdominal aortic aneurysms (LPL, 0.64, 0.44–0.94). The gene discussed is ANGPTL3; the disease is abdominal aortic aneurysm.